Table 1 Patient characteristics. Group I received concurrent cisplatin and group II received concurrent paclitaxel.

Number of patients

16 *

15 *

Median age (years)

56 (37-71) *

48 (38-80) *

Parity

4 (0-11) *

5 (2-9) *

Squamous cell pathology

13 (81%) *

14 (93%) *

Stage III-IVA

7 (44%) *

8(53%) *

Median Tumor size (cm)

4.75 (2.5-8) *

6 (3-11) *

Hydronephrosis

3 (19%) *

5 (33%) *

Positive pelvic lymph nodes

3 (19%) *

5 (33%) *

Enrolled as pelvic recurrence

2 (13%) *

5 (33%) *